Australia - English - Department of Health (Therapeutic Goods Administration)

draeger australia pty ltd - 57793 - public respirator, single-use - the drager x-plore 1700 series particle filtering half masks reduce the amount of harmful particles in the inhaled air. they can be used to protect against solid and liquid nonvolatile particles

Australia - English - Department of Health (Therapeutic Goods Administration)

draeger australia pty ltd - 34858 - suction system canister, single-use - disposable cartridge for collecting secretion in the secretion bottles of the drager bronchial aspirators

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - midodrine hydrochloride 2.5mg - tablet - 2.5 mg - active: midodrine hydrochloride 2.5mg excipient: hydrated silica magnesium stearate microcrystalline cellulose purified talc starch - gutron is indicated to attenuate symptoms of chronic orthostatic hypotension due to automatic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including non-pharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of gutron therapy should be undertaken under close medical supervision in a controlled clinical setting.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - midodrine hydrochloride 5mg - tablet - 5 mg - active: midodrine hydrochloride 5mg excipient: hydrated silica magnesium stearate microcrystalline cellulose purified talc starch sunset yellow fcf - gutron is indicated to attenuate symptoms of chronic orthostatic hypotension due to automatic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including non-pharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of gutron therapy should be undertaken under close medical supervision in a controlled clinical setting.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - midodrine hydrochloride 2.5mg - tablet - 2.5 mg - active: midodrine hydrochloride 2.5mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose purified talc - midodrine hydrochloride is indicated to attenuate symptoms of chronic orthostatic hypotension due to autonomic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including nonpharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of midodrine hydrochloride therapy should be undertaken under close medical supervision in a controlled clinical setting.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - midodrine hydrochloride 2.5mg - tablet - 2.5 mg - active: midodrine hydrochloride 2.5mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose purified talc - midodrine hydrochloride is indicated to attenuate symptoms of chronic orthostatic hypotension due to autonomic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including nonpharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of midodrine hydrochloride therapy should be undertaken under close medical supervision in a controlled clinical setting.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - midodrine hydrochloride 5mg - tablet - 5 mg - active: midodrine hydrochloride 5mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose purified talc sunset yellow aluminium lake - midodrine hydrochloride is indicated to attenuate symptoms of chronic orthostatic hypotension due to autonomic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including nonpharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of midodrine hydrochloride therapy should be undertaken under close medical supervision in a controlled clinical setting.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - midodrine hydrochloride 5mg - tablet - 5 mg - active: midodrine hydrochloride 5mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose purified talc sunset yellow aluminium lake - midodrine hydrochloride is indicated to attenuate symptoms of chronic orthostatic hypotension due to autonomic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including nonpharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of midodrine hydrochloride therapy should be undertaken under close medical supervision in a controlled clinical setting.